Paul M. O'Byrne
- Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthmaBy Ashley Woodcock, Eugene R. Bleecker, Jan Lötvall, Paul M. O'Byrne, Eric D. Bateman, Hilary Medley, Anna Ellsworth, Loretta Jacques and William W BusseAshley Woodcock1School of Translational Medicine, University of Manchester, United KingdomEugene R. Bleecker2Center for Genomics and Personalized Medicine, Wake Forest School of Medicine, Winston-Salem, United StatesJan Lötvall3Krefting Research Center, University of Gothenburg, SwedenPaul M. O'Byrne4Michael G DeGroote School of Medicine, McMaster University, Hamilton, CanadaEric D. Bateman5Department of Medicine, University of Cape Town, South AfricaHilary Medley6Respiratory Medicines Development Centre, GlaxoSmithKline, Uxbridge, United KingdomAnna Ellsworth7Quantitative Sciences Division, GlaxoSmithKline, Research Triangle Park, United StatesLoretta Jacques6Respiratory Medicines Development Centre, GlaxoSmithKline, Uxbridge, United KingdomWilliam W Busse8Department of Medicine, University of Wisconsin, Madison, United Kingdom
- Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long-acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthmaBy William W. Busse, Paul M. O'Byrne, Eugene R. Bleecker, Jan Lötvall, Ashley Woodcock, Leslie Andersen, Jody West, Loretta Jacques, Ludovic Apoux and Eric D. BatemanWilliam W. Busse1Department of Medicine, University of Wisconsin, Madison, United StatesPaul M. O'Byrne2Michael G DeGroote School of Medicine, McMaster University, Hamilton, CanadaEugene R. Bleecker3Center for Genomics and Personalized Medicine, Wake Forest School of Medicine, Winston-Salem, United StatesJan Lötvall4Krefting Research Centre, University of Gothenburg, SwedenAshley Woodcock5School of Translational Medicine, University of Manchester, United StatesLeslie Andersen6Respiratory Medicines Development Center, GlaxoSmithKline, Research Triangle Park, United StatesJody West7Quantitative Sciences Division, GlaxoSmithKline, Uxbridge, United KingdomLoretta Jacques8Respiratory Medicine Development Centre, GlaxoSmithKline, Uxbridge, United KingdomLudovic Apoux9Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline, Uxbridge, United KingdomEric D. Bateman10Department of Medicine, University of Cape Town, South Africa
- Effect of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) on risk of severe exacerbations in asthmaBy Eric D. Bateman, Paul M. O'Byrne, William W. Busse, Jan Lötvall, Eugene R. Bleecker, Leslie Andersen, Brett Haumann, Lucy Frith, Jessica Lim, Loretta Jacques and Ashley WoodcockEric D. Bateman1Department of Medicine, University of Cape Town, South AfricaPaul M. O'Byrne2Michael G DeGroote School of Medicine, McMaster University, Hamilton, CanadaWilliam W. Busse3Department of Medicine, University of Wisconsin, Madison, United StatesJan Lötvall4Krefting Research Centre, University of Gothenburg, SwedenEugene R. Bleecker5Center for Genomics and Personalized Medicine, Wake Forest University Health Sciences, Winston-Salem, United StatesLeslie Andersen6Respiratory Medicines Development Center, GlaxoSmithKline, Research Triangle Park, United StatesBrett Haumann7Respiratory Medicines Development Centre, GlaxoSmithKline, Uxbridge, United KingdomLucy Frith8Quantitative Sciences Division, GlaxoSmithKline, Uxbridge, United KingdomJessica Lim8Quantitative Sciences Division, GlaxoSmithKline, Uxbridge, United KingdomLoretta Jacques7Respiratory Medicines Development Centre, GlaxoSmithKline, Uxbridge, United KingdomAshley Woodcock9School of Translational Medicine, University of Manchester, United Kingdom
- Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) for 24 weeks in persistent asthmaBy Paul M. O'Byrne, Eugene R. Bleecker, Eric D. Bateman, William W. Busse, Ashley Woodcock, Richard Forth, Tom Toler, Loretta Jacques and Jan LötvallPaul M. O'Byrne1Michael G DeGroote School of Medicine, McMaster University, Hamilton, CanadaEugene R. Bleecker2Center for Genomics and Personalized Medicine, Wake Forest University Health Sciences, Winston-Salem, United StatesEric D. Bateman3Department of Medicine, University of Cape Town, South AfricaWilliam W. Busse4Department of Medicine, University of Wisconsin, Madison, United StatesAshley Woodcock5School of Translational Medicine, University of Manchester, United KingdomRichard Forth6Quantitative Sciences Division, GlaxoSmithKline, Research Triangle Park, United StatesTom Toler7Respiratory Medicines Development Center, GlaxoSmithKline, Research Triangle Park, United StatesLoretta Jacques8Respiratory Medicines Development Centre, GlaxoSmithKline, Uxbridge, United KingdomJan Lötvall9Krefting Research Centre, University of Gothenburg, Sweden
- Efficacy and safety of once-daily (OD) fluticasone furoate (FF) 50mcg over 24 weeks in adults and adolescents with persistent asthmaBy William W. Busse, Eric D. Bateman, Paul M. O'Byrne, Jan Lötvall, Ashley Woodcock, Hilary Medley, Richard Forth, Loretta Jacques and Eugene R. BleeckerWilliam W. Busse1Department of Medicine, University of Wisconsin, Winston-Salem, United StatesEric D. Bateman2Department of Medicine, University of Cape Town, Cape Town, South AfricaPaul M. O'Byrne3Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, CanadaJan Lötvall4Krefting Research Centre, University of Gothenburg, Gothenburg, SwedenAshley Woodcock5Institute of Inflammation and Repair, University of Manchester, Manchester, United KingdomHilary Medley6Respiratory Medicines Development Centre, GlaxoSmithKline, London, United KingdomRichard Forth7Quantitative Sciences Division, GlaxoSmithKline, Research Triangle Park, United StatesLoretta Jacques6Respiratory Medicines Development Centre, GlaxoSmithKline, London, United KingdomEugene R. Bleecker8Center for Human Genomics and Personalized Medicine, Wake Forest School of Medicine, Winston-Salem, United States
- Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in adults and adolescents with moderate-to-severe persistent asthmaBy Ashley Woodcock, Jan Lötvall, Eugene R. Bleecker, William W. Busse, Paul M. O'Byrne, Eric D. Bateman, Sally Stone, Anna Ellsworth and Loretta JacquesAshley Woodcock1Institute of Inflammation and Repair, University of Manchester, Manchester, United KingdomJan Lötvall2Krefting Research Centre, University of Gothenburg, Gothenburg, SwedenEugene R. Bleecker3Center for Human Genomics and Personalized Medicine, Wake Forest School of Medicine, Winston-Salem, United StatesWilliam W. Busse4Department of Medicine, University of Wisconsin, Madison, United StatesPaul M. O'Byrne5Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, CanadaEric D. Bateman6Department of Medicine, University of Cape Town, Cape Town, South AfricaSally Stone7Respiratory Medicines Discovery and Development, GlaxoSmithKline, London, United KingdomAnna Ellsworth8Quantitative Sciences Division, GlaxoSmithKline, Durham, United StatesLoretta Jacques7Respiratory Medicines Discovery and Development, GlaxoSmithKline, London, United Kingdom
- Peripheral blood Th17 / Treg ratio increases in late asthmatic responseBy Masatsugu Yamamoto, Amrit Singh, Jian Ruan, Gail M. Gauvreau, Sven Olek, Ulrich Hoffmueller, Paul M. O'Byrne, Christopher R. Carlsten, J. Mark FitzGerald, Louis-Philippe Boulet and Scott J. TebbuttMasatsugu Yamamoto1James Hogg Research Centre, St. Paul's Hospital, University of British Columbia, Vancouver, Canada2Institute for HEART + LUNG Health, University of British Columbia, Vancouver, Canada3Department of Medicine, Division of Respiratory Medicine, University of British Columbia, Vancouver, Canada4Vancouver Coastal Health Research Institute, Vancouver General Hospital, Vancouver, CanadaAmrit Singh1James Hogg Research Centre, St. Paul's Hospital, University of British Columbia, Vancouver, Canada2Institute for HEART + LUNG Health, University of British Columbia, Vancouver, Canada3Department of Medicine, Division of Respiratory Medicine, University of British Columbia, Vancouver, Canada5NCE CECR PROOF Centre of Excellence, University of British Columbia, Vancouver, CanadaJian Ruan1James Hogg Research Centre, St. Paul's Hospital, University of British Columbia, Vancouver, Canada2Institute for HEART + LUNG Health, University of British Columbia, Vancouver, Canada5NCE CECR PROOF Centre of Excellence, University of British Columbia, Vancouver, CanadaGail M. Gauvreau6Department of Medicine, McMaster University, Hamilton, CanadaSven Olek7Epiontis, GmbH, Berlin, GermanyUlrich Hoffmueller7Epiontis, GmbH, Berlin, GermanyPaul M. O'Byrne6Department of Medicine, McMaster University, Hamilton, CanadaChristopher R. Carlsten1James Hogg Research Centre, St. Paul's Hospital, University of British Columbia, Vancouver, Canada2Institute for HEART + LUNG Health, University of British Columbia, Vancouver, Canada3Department of Medicine, Division of Respiratory Medicine, University of British Columbia, Vancouver, Canada4Vancouver Coastal Health Research Institute, Vancouver General Hospital, Vancouver, CanadaJ. Mark FitzGerald2Institute for HEART + LUNG Health, University of British Columbia, Vancouver, Canada3Department of Medicine, Division of Respiratory Medicine, University of British Columbia, Vancouver, Canada4Vancouver Coastal Health Research Institute, Vancouver General Hospital, Vancouver, CanadaLouis-Philippe Boulet8Quebec Heart and Lung Institute, Laval University, Quebec City, CanadaScott J. Tebbutt1James Hogg Research Centre, St. Paul's Hospital, University of British Columbia, Vancouver, Canada2Institute for HEART + LUNG Health, University of British Columbia, Vancouver, Canada3Department of Medicine, Division of Respiratory Medicine, University of British Columbia, Vancouver, Canada5NCE CECR PROOF Centre of Excellence, University of British Columbia, Vancouver, Canada
- Ease of use of a two-strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthmaBy Henrik Svedsater, Loretta Jacques, Caroline Goldfrad, Eugene R. Bleecker, Paul M. O'Byrne and Ashley WoodcockHenrik Svedsater1Global Health Outcomes, GlaxoSmithKline, London, United KingdomLoretta Jacques2Respiratory Medicines Discovery and Development, GlaxoSmithKline, London, United KingdomCaroline Goldfrad3Quantitative Sciences Division, GlaxoSmithKline, London, United KingdomEugene R. Bleecker4Center for Human Genomics and Personalized Medicine, Wake Forest School of Medicine, Winston-Salem, United StatesPaul M. O'Byrne5Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, CanadaAshley Woodcock6Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom
- Late-breaking abstract: Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting the allergen-induced early asthmatic responseBy Gail M. Gauvreau, Louis-Philippe Boulet, Richard Leigh, Donald W. Cockcroft, Beth E. Davis, Irvin Mayers, J Mark FitzGerald, Barbro Dahlen, Richard M. Watson, Joanne Milot, Veronica Swystun, Linda Hui, Ann-Sofie Lantz, Miranda Bowen, Jonathan Arm, Suzzane Maahs, Karin Meiser, Philip Lowe, Andrej Skerjanec, Christopher Carlsten, Karin Strandberg, Kieran J. Killian, Michele Laviolette, Anton Drollmann and Paul M. O'ByrneGail M. Gauvreau1Department of Medicine, McMaster University, Hamilton, ON, CanadaLouis-Philippe Boulet2Department of Medicine, Université Laval, Québec, QC, CanadaRichard Leigh3Medicine and Physiology and Pharmacology, University of Calgary, Calgary, AB, CanadaDonald W. Cockcroft4Department of Medicine, University of Saskatchewan, Royal University Hospital, Saskatoon, SK, CanadaBeth E. Davis4Department of Medicine, University of Saskatchewan, Royal University Hospital, Saskatoon, SK, CanadaIrvin Mayers5Department of Medicine, University of Alberta, Edmonton, AB, CanadaJ Mark FitzGerald6Department of Medicine, University of British Columbia, Vancouver, BC, CanadaBarbro Dahlen7Karolinska Institutet (KI), Department of Medicine, Karolinska University, Stockholm, SwedenRichard M. Watson1Department of Medicine, McMaster University, Hamilton, ON, CanadaJoanne Milot2Department of Medicine, Université Laval, Québec, QC, CanadaVeronica Swystun3Medicine and Physiology and Pharmacology, University of Calgary, Calgary, AB, CanadaLinda Hui6Department of Medicine, University of British Columbia, Vancouver, BC, CanadaAnn-Sofie Lantz7Karolinska Institutet (KI), Department of Medicine, Karolinska University, Stockholm, SwedenMiranda Bowen5Department of Medicine, University of Alberta, Edmonton, AB, CanadaJonathan Arm8Novartis Institutes for Biomedical Research, Novartis, Basel, SwitzerlandSuzzane Maahs9Novartis Institutes for Biomedical Research, Novartis, East Hanover, NJ,Karin Meiser10Integrated Information Sciences, Novartis Pharma AG, Basel, SwitzerlandPhilip Lowe10Integrated Information Sciences, Novartis Pharma AG, Basel, SwitzerlandAndrej Skerjanec8Novartis Institutes for Biomedical Research, Novartis, Basel, SwitzerlandChristopher Carlsten6Department of Medicine, University of British Columbia, Vancouver, BC, CanadaKarin Strandberg7Karolinska Institutet (KI), Department of Medicine, Karolinska University, Stockholm, SwedenKieran J. Killian1Department of Medicine, McMaster University, Hamilton, ON, CanadaMichele Laviolette2Department of Medicine, Université Laval, Québec, QC, CanadaAnton Drollmann8Novartis Institutes for Biomedical Research, Novartis, Basel, SwitzerlandPaul M. O'Byrne1Department of Medicine, McMaster University, Hamilton, ON, Canada
- Allergen-induced airway responsesBy Gail M. Gauvreau, Amani I. El-Gammal and Paul M. O'ByrneArticle | Published in 2015 in European Respiratory JournalGail M. GauvreauFirestone Institute for Respiratory Health and the Department of Medicine, McMaster University, Hamilton, ON, CanadaAmani I. El-GammalFirestone Institute for Respiratory Health and the Department of Medicine, McMaster University, Hamilton, ON, CanadaPaul M. O'ByrneFirestone Institute for Respiratory Health and the Department of Medicine, McMaster University, Hamilton, ON, Canada
- A summary of the new GINA strategy: a roadmap to asthma controlBy Helen K. Reddel, Eric D. Bateman, Allan Becker, Louis-Philippe Boulet, Alvaro A. Cruz, Jeffrey M. Drazen, Tari Haahtela, Suzanne S. Hurd, Hiromasa Inoue, Johan C. de Jongste, Robert F. Lemanske, Mark L. Levy, Paul M. O'Byrne, Pierluigi Paggiaro, Soren E. Pedersen, Emilio Pizzichini, Manuel Soto-Quiroz, Stanley J. Szefler, Gary W.K. Wong and J. Mark FitzGeraldArticle | Published in 2015 in European Respiratory JournalHelen K. Reddel1Woolcock Institute of Medical Research, University of Sydney, Sydney, AustraliaEric D. Bateman2University of Cape Town Lung Institute, Cape Town, South AfricaAllan Becker3University of Manitoba, Winnipeg, MB, CanadaLouis-Philippe Boulet4Quebec Heart and Lung Institute, Laval University, Québec City, QC, CanadaAlvaro A. Cruz5Federal University of Bahia, Salvador, BrazilJeffrey M. Drazen6Harvard Medical School, Boston, MA, USATari Haahtela7Helsinki University Central Hospital, Helsinki, FinlandSuzanne S. Hurd8Global Initiative for Asthma, Vancouver, WA, USAHiromasa Inoue9Kagoshima University, Kagoshima, JapanJohan C. de Jongste10Dept of Pediatrics, Erasmus University Medical Centre, Rotterdam, The NetherlandsRobert F. Lemanske Jr11University of Wisconsin, Madison, WI, USAMark L. Levy12General Practitioner, London, UKPaul M. O'Byrne13Firestone Institute of Respiratory Health, St. Joseph's Healthcare and McMaster University, Hamilton, ON, CanadaPierluigi Paggiaro14University of Pisa, Pisa, ItalySoren E. Pedersen15Pediatric Research Unit, University of Southern Denmark, Kolding Hospital, Kolding, DenmarkEmilio Pizzichini16Universidade Federal de Santa Catarina, NUPAIVA Asthma Research Centre, Florianópolis, BrazilManuel Soto-Quiroz17National Childreńs Hospital, University of Costa Rica San Jose, San Jose, Costa RicaStanley J. Szefler18Children's Hospital Colorado, Aurora, CO, USAGary W.K. Wong19Dept of Paediatrics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong KongJ. Mark FitzGerald20Institute for Heart and Lung Health, University of British Columbia, Vancouver, BC, Canada
- A summary of the new GINA strategy: a roadmap to asthma controlBy Helen K. Reddel, Eric D. Bateman, Allan Becker, Louis-Philippe Boulet, Alvaro A. Cruz, Jeffrey M. Drazen, Tari Haahtela, Suzanne S. Hurd, Hiromasa Inoue, Johan C. de Jongste, Robert F. Lemanske, Mark L. Levy, Paul M. O'Byrne, Pierluigi Paggiaro, Soren E. Pedersen, Emilio Pizzichini, Manuel Soto-Quiroz, Stanley J. Szefler, Gary W.K. Wong and J. Mark FitzGeraldHelen K. Reddel1Woolcock Institute of Medical Research, University of Sydney, Sydney, AustraliaEric D. Bateman2University of Cape Town Lung Institute, Cape Town, South AfricaAllan Becker3University of Manitoba, Winnipeg, MB, CanadaLouis-Philippe Boulet4Quebec Heart and Lung Institute, Laval University, Québec City, QC, CanadaAlvaro A. Cruz5Federal University of Bahia, Salvador, BrazilJeffrey M. Drazen6Harvard Medical School, Boston, MA, USATari Haahtela7Helsinki University Central Hospital, Helsinki, FinlandSuzanne S. Hurd8Global Initiative for Asthma, Vancouver, WA, USAHiromasa Inoue9Kagoshima University, Kagoshima, JapanJohan C. de Jongste10Dept of Pediatrics, Erasmus University Medical Centre, Rotterdam, The NetherlandsRobert F. Lemanske Jr11University of Wisconsin, Madison, WI, USAMark L. Levy12General Practitioner, London, UKPaul M. O'Byrne13Firestone Institute of Respiratory Health, St. Joseph's Healthcare and McMaster University, Hamilton, ON, CanadaPierluigi Paggiaro14University of Pisa, Pisa, ItalySoren E. Pedersen15Pediatric Research Unit, University of Southern Denmark, Kolding Hospital, Kolding, DenmarkEmilio Pizzichini16Universidade Federal de Santa Catarina, NUPAIVA Asthma Research Centre, Florianópolis, BrazilManuel Soto-Quiroz17National Childreńs Hospital, University of Costa Rica San Jose, San Jose, Costa RicaStanley J. Szefler18Children's Hospital Colorado, Aurora, CO, USAGary W.K. Wong19Dept of Paediatrics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong KongJ. Mark FitzGerald20Institute for Heart and Lung Health, University of British Columbia, Vancouver, BC, Canada
- Allergen-induced airway responsesBy Gail M. Gauvreau, Amani I. El-Gammal and Paul M. O'ByrneGail M. GauvreauFirestone Institute for Respiratory Health and the Department of Medicine, McMaster University, Hamilton, ON, CanadaAmani I. El-GammalFirestone Institute for Respiratory Health and the Department of Medicine, McMaster University, Hamilton, ON, CanadaPaul M. O'ByrneFirestone Institute for Respiratory Health and the Department of Medicine, McMaster University, Hamilton, ON, Canada
- QGE031 (ligelizumab) is more effective than omalizumab and placebo in inhibiting allergen-induced early asthmatic response: Results from a predictive modeling studyBy Gail M. Gauvreau, Louis-Philippe Boulet, Richard Leigh, Donald W. Cockcroft, Beth E. Davis, Irvin Mayers, J. Mark FitzGerald, Barbro Dahlen, R.M. Watson, Joanne Milot, Veronica Swystun, Linda Hui, Ann-Sofie Lantz, Miranda Bowen, Jonathan Arm, Suzzane Maahs, Karin Meiser, Philip Lowe, Andrej Skerjanec, Christopher Carlsten, Karin Strandberg, Kieran J. Killian, Michele Laviolette, Anton Drollmann and Paul M. O'ByrneGail M. Gauvreau1Cardio-Respiratory Lab, McMaster University, Hamilton, ON CanadaLouis-Philippe Boulet2Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, QC CanadaRichard Leigh3Faculty of Medicine, University of Calgary, Caldary, AB CanadaDonald W. Cockcroft4Respirology, Critical Care and Sleep Medicine, University of Saskatchewan, Saskatoon, SK CanadaBeth E. Davis4Respirology, Critical Care and Sleep Medicine, University of Saskatchewan, Saskatoon, SK CanadaIrvin Mayers5Department of Medicine, University of Alberta, Edmonton, AB CanadaJ. Mark FitzGerald6Respiratory Medicine, University of British Columbia, Vancouver, BC CanadaBarbro Dahlen7Unit of Heart and Lung Diseases, Karolinska University, Stockholm, SwedenR.M. Watson1Cardio-Respiratory Lab, McMaster University, Hamilton, ON CanadaJoanne Milot2Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, QC CanadaVeronica Swystun3Faculty of Medicine, University of Calgary, Caldary, AB CanadaLinda Hui6Respiratory Medicine, University of British Columbia, Vancouver, BC CanadaAnn-Sofie Lantz7Unit of Heart and Lung Diseases, Karolinska University, Stockholm, SwedenMiranda Bowen5Department of Medicine, University of Alberta, Edmonton, AB CanadaJonathan Arm8Novartis Institutes for Biomedical Research, Basel, SwitzerlandSuzzane Maahs9Novartis Institutes for Biomedical Research, East Hanover, NJ United StatesKarin Meiser10Novartis Pharma AG, Basel, SwitzerlandPhilip Lowe10Novartis Pharma AG, Basel, SwitzerlandAndrej Skerjanec10Novartis Pharma AG, Basel, SwitzerlandChristopher Carlsten6Respiratory Medicine, University of British Columbia, Vancouver, BC CanadaKarin Strandberg7Unit of Heart and Lung Diseases, Karolinska University, Stockholm, SwedenKieran J. Killian1Cardio-Respiratory Lab, McMaster University, Hamilton, ON CanadaMichele Laviolette2Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, QC CanadaAnton Drollmann8Novartis Institutes for Biomedical Research, Basel, SwitzerlandPaul M. O'Byrne1Cardio-Respiratory Lab, McMaster University, Hamilton, ON Canada
- ERS Handbook of Respiratory MedicineEdited by Paolo Palange and Gernot RohdeBook | Published in 2019DOI: 10.1183/9781849840798.erh01ISBN (electronic): 978-1-84984-079-8
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.